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Abstract
AS1411 binds nucleolin (NCL) and is the first oligodeoxynucleotide aptamer to reach phase
I and II clinical trials for the treatment of several cancers. However, the mechanisms by
which AS1411 targets and kills glioma cells and tissues remain unclear. Here we report that
AS1411 induces cell apoptosis and cycle arrest, and inhibits cell viability by up-regulation of
p53 and down-regulation of Bcl-2 and Akt1 in human glioma cells. NCL was overexpressed
in both nucleus and cytoplasm in human glioma U87, U251 and SHG44 cells compared to
normal human astrocytes (NHA). AS1411 bound NCL and inhibited the proliferation of gli-
oma cells but not NHA, which was accompanied with up-regulation of p53 and down-regula-
tion of Bcl-2 and Akt1. Moreover, AS1411 treatment resulted in the G2/M cell cycle arrest in
glioma cells, which was however abolished by overexpression of NCL. Further, AS1411
induced cell apoptosis, which was prevented by silencing of p53 and overexpression of Bcl-
2. In addition, AS1411 inhibited the migration and invasion of glioma cells in an Akt1-depen-
dent manner. Importantly, AS1411 inhibited the growth of glioma xenograft and prolonged
the survival time of glioma tumor-bearing mice. These results revealed a promising treat-
ment of glioma by oligodeoxynucleotide aptamer.
Introduction
Glioblastoma (GBM) is one of the most common and devastating primary malignant intracra-
nial tumors in human. The current therapy for newly diagnosed GBM is surgical resection fol-
lowed by radiotherapy plus chemotherapy [1]. However, the prognosis is poor with a median
overall survival of only 14.6 months, median progression free survival of 6.9 months and 5
year survival rate of only 9.8% after diagnosis [1, 2]. The treatment failure mainly results from
the resistance of malignant glioma cells to current therapeutic modules [3], it is thus in urgent
need to identify effective modalities for the management of glioma patients.
Aptamers are designed as 12–30 bases oligonucleotides (ssDNA or RNA), or peptides. They
were first identified from basic science studies with viruses in the 1980s and have been found
PLOS ONE | DOI:10.1371/journal.pone.0167094 December 1, 2016 1 / 20
a11111
OPENACCESS
Citation: Cheng Y, Zhao G, Zhang S, Nigim F, Zhou
G, Yu Z, et al. (2016) AS1411-Induced Growth
Inhibition of Glioma Cells by Up-Regulation of p53
and Down-Regulation of Bcl-2 and Akt1 via
Nucleolin. PLoS ONE 11(12): e0167094.
doi:10.1371/journal.pone.0167094
Editor: Ilya Ulasov, Swedish Neuroscience
Institute, UNITED STATES
Received: July 20, 2016
Accepted: November 7, 2016
Published: December 1, 2016
Copyright: © 2016 Cheng et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which
permits unrestricted use, distribution, and
reproduction in any medium, provided the original
author and source are credited.
Data Availability Statement: All relevant data are
within the paper and its Supporting Information
files
Funding: This work was supported by grants from
National Natural Science Foundation of China (Nos.
21401072 and 81672505). This work was
supported by China Scholarship Council. The
funders had no role in study design, data collection
and analysis, decision to publish, or preparation of
the manuscript.
to possess good pharmaceutical properties of drugs [4–5]. Aptamers have increased resistance
to serum nucleases and enhanced cellular uptake compared to unstructured molecules. More-
over, quadruplex oligonucleotides are non-immunogenic and heat stable [6]. Therefore, apta-
mers are promising for the development as drugs for the treatment of various human diseases,
including cancers, with numerous aptamers in pre-clinic and clinic trials. AS1411 was devel-
oped by Antisoma plc and is the first oligodeoxynucleotide aptamer to reach phase I and II
clinical trials for the treatment of cancers, including acute myelogenous leukemia (AML) [7],
prostatic cancer [8], and breast cancer [9]. AS1411 can be conjugated with blood-brain barrier
(BBB) penetrating peptides which make it a good therapeutic agent for brain tumor [10–11].
Although AS1411 induces cytotoxicity on GBM in vitro and in vivo [12], the related mecha-
nisms remain unclear. Understanding the effect of AS1411 on glioma may solve drug resis-
tance of GBM and promote further therapeutic strategies.
It has been found that the main pharmacology of AS1411 is to interfere nucleolin (NCL), a
protein that has the ability to bind to G-quadruplex-forming DNA sequences [12]. The expres-
sion of NCL is correlated with cell proliferative status and its protein level is being widely used
as a bio-marker of cell proliferation; moreover, NCL expression has been shown to associate
with the development and progression of various cancers [13]. GBM is an aggressive tumor
with overexpression of NCL [14]. These facts lead us to speculate that AS1411 may have poten-
tial therapeutic effects for GBM via NCL.
In the present study, we investigated the anti-tumor effect of AS1411 on glioma cells both
in vitro and in vivo. The novelty is that we found AS1411 can up-regulate p53 and down-regu-
late Bcl-2 and Akt1 via NCL hence inhibit growth and proliferation of glioma cells. In mouse
GBM xenografts, AS1411 significantly reduced the tumor burden and prolonged the median
survival of tumor bearing mice. Our results suggest that AS1411 is a promising agent for the
treatment of GBM.
Materials and Methods
Ethic statement and patient samples
The study protocol was approved by the Medical Ethics and Human Clinical Trial Committee
of First Hospital of Jilin University. All the patients or their relatives have provided written
consent to participate in this study. The experiments were performed in accordance with rele-
vant guidelines and regulations. Diagnosis of GBM was histopathologically confirmed by 2
pathologists according to WHO carcinoma. The clinicopathological characteristics of patients
were shown in Table 1.
Cell culture and oligonucleotides
Human glioma U87, U251 cells were obtained from American type culture collection
(ATCC). SHG44 cells were obtained from the Cell Bank of the Chinese Academy of Science
(Shanghai, China). Normal human astrocytes (NHA) were obtained from four 13-week-old
embryos aborted from patients in the First Hospital of Jilin University. NHA cells were dif-
ferentiated and purified in vitro (S1 Fig and S1 File). The glioma cells were grown in Dulbec-
co’s modified eagle medium (DMEM, Gibco) supplemented with 10% fetal bovine serum
(FBS) (Biowest, Nuaille´, France). NHA were cultured with astrocyte media (Invitrogen) con-
taining 10% FBS. Cells were cultured in a humidified incubator maintained at 37˚C with 95%
air and 5% CO2. AS1411, with sequence 5’-d(GGTGGTGGTGGTTGTGGTGGTGGTGG)-3’
and an inactive control oligonucleotide (CRO) (no anti-proliferative activity), 5’d
(CCTCCTCCTCCTTCTCCTCCTCCTCC)-3’ as well as 5’-FITC-AS1411, had a phos-
phodiester backbone and were purchased in the desalted form from Sangon Biotech
Effect of AS1411 on Glioma via Nucleolin
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(Shanghai, China). Aptamers were dissolved in DMEM (without serum) before treatment
and stored at -80˚C where the solution can be stable for over 6 months.
Cell viability detection
MTT assay was used the assessment of cell viability. U87, U251, SHG44 and NHA cells were
seeded in 96-well plate and exposed to AS1411 at concentration of 0, 2.5, 5, 10μM or 10μM
CRO for 24h, 48h, 72h and 96h (NHA for 48h). 20μl MTT (5 mg/ml) (Promega, Shanghai,
China) was added to each well and incubated for 4h. Dimethyl Sulphoxide (DMSO) was added
to the well after discarding the supernatant. Then, the plate was shaken for 3min. The absor-
bance was measured at 570nm wavelength using a Microplate Reader (Bio-Rad, Hercules, CA,
USA).
Immunohistochemical staining
Immunohistochemical studies were performed as previously reported [15]. Normal brain tis-
sue was obtained from a frontal lobe trauma patients. Deep gray matter in frontal lobe was
used. The sections were incubated with a monoclonal antibody specific for NCL (Santa Cruz,
CA) at a 1:100 dilution overnight at 4˚C for 24h, and then detected using biotinylated second-
ary antibodies (Zhongshan Golden Bridge Biotechnology Ltd. Co., China) based on the manu-
facturer’s protocols. The staining of the slides was carried out by the HRP-streptavidin
conjugates. The slides were visualized with diaminobenzidine, and then counterstained with
hematoxylin. PBS was used instead of the primary antibodies for the negative controls.
Flow cytometric assays
Cells were plated at 105 cells per well in six-well plates and exposed to 0, 2.5, 5μM AS1411 or
5μM CRO for 48h. For the detection of cell cycle distribution, cells were fixed in 70% ethanol
Table 1. Clinical characteristics in archival GBM patients.
Factor Cases
Gender
Male 22
Female 18
Age (Years)
< 50 21
 50 19
KPS
< 75 18
 75 22
Extent of resection
GTR 25
STR 15
Tumor size (cm)
< 6 22
 6 18
KPS: Karnofsky Performance Score.
GTR: Gross-total Resection.
STR: Subtotal Resection.
doi:10.1371/journal.pone.0167094.t001
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for 12h at -20˚C after collection, then washed twice with PBS, and incubated with 1g/ml propi-
dium iodide (PI) and RNase for 25min. For the detection of cell apoptosis, FITC Annexin V
Apoptosis Dectection Kit (BD Pharmingen) was used. Cells were washed with PBS, followed
by incubation with PI and FITC Annexin V for 15min according to the manufacturer’s
instructions.
siRNA interference and gene over-expression
The sequences of NCL siRNA duplexes were 5’-GGUCGUCAUACCUCAGAAGtt; The
sequences of p53 siRNA duplexes were 5'-CUACUUCCUGAAAACAACGdTdT-3';5'-
CGUUGUUUUCAGGAAGUAGdTdT-3. The siRNAs were chemically synthesized and annealed
by Ambion (Austin, TX) and transfected using X-tremeGENE HP DNA Transfection Reagent
(Roche) according to the manufacturer’s directions. The scrambled siRNA used as a negative
control was from Ambion. For the gene overexpression, pCEP4 Bcl-2 (Plasmid #16461),
pCDH-puro-myr-HA-Akt1 (Plasmid #46969) and GFP-Nucleolin (Plasmid #28176) were
obtained from the Addgene (Cambridge, MA). The genes were amplified by PCR and cloned
into the corresponding cloning sites in the pcDNA3.1/myc mammalian expression vector. The
plasmids were transfected with Lipofectamine 2000 (Invitrogen) following the manufacturer’s
instruction. 48 h after transfection, positive transfected cells were selected with 600 μg/ml
G418. The Myc tag was detected by western blotting.
Immunoblotting
Immunoblotting was performed as previously reported [16]. In brief, total proteins were
extracted from the cultured cells with radioimmunoprecipitation (RIPA) assay buffer (Cell Sig-
naling Technology, Boston, MA). Samples containing 30–35μg of total protein were loaded
onto 8–12% SDS polyacrylamide gel electrophoresis (PAGE), transferred onto a nitrocellulose
membrane (Roche), and probed with primary antibodies. Anti-bcl-2, anti-NCL, anti-Akt1,
anti-cyclin A1, anti-cyclin B1, and anti-cyclin D1 antibodies were purchased from Santa Cruz
Biotechnology (Santa Cruz, CA). Anti-actin antibody (AC-40) was purchased from Sigma-
Alderich; Anti-p53 monoclonal antibody (clone Y5) was purchased from abcam (Cambridge,
MA). Following incubation with HRP-conjugated goat anti-rabbit, or goat anti-mouse second-
ary antibodies (ZSGB-BIO), protein bands were visualized by an ECL plus chemiluminescence
kit (Beyotime, Haimen, China).
Immunofluorescence
Immunofluorescence was performed as previously reported [17]. Cells were fixed in 2% form-
aldehyde and permeabilized in 0.25% Triton X100 in phosphate buffered saline (PBS) for 5
min at room temperature. Cells were then incubated with primary antibodies (anti-NCL),
washed in PBS and incubated with the fluorophore-conjugated secondary antibodies. The fol-
lowing secondary antibodies were used: Rhodamine or DyLightTM488 conjugated goat anti-
rabbit, fluorescein or DyLightTM594 conjugated goat anti-mouse (ZSGB-BIO). Fluorescence
signals were captured by using Olympus Fluoview FV1000 confocal microscope and analyzed
by FV10-ASW 1.6 Viewer program (Olympus, Japan).
Real-time RT-PCR
The final Bcl-2, p53 and NCL primer concentrations were 900nM, and PCR amplification was
subjected to 35 cycles of 95˚C for 15 sec, 54˚C for 2 min. The primer sequences were as follow-
ing: Bcl-2: (forward) 5-ATGTGTGTGGAGAGCGTCAA-3, (reverse)
Effect of AS1411 on Glioma via Nucleolin
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5-TAACTATCCTTGCCCGAACG-3 [9]; p53: (forward) 5'-AGGTTGGCTCTGACTGTA-3',
(reverse) 5'-CCTCTGTCT-TGAACATGA-3'; NCL: (forward)5’-GCACTTGGAGTGGT
GAATCAAA-3’, (reverse) 5’-AAATGCATACCCTTTAGATTTGCC-3’ [9]. Quantitative PCR
was done using the SYBR green Jumpstart Taq ReadyMix (TaKaRa) on a Roche LightCycler
480. Reverse transcription involved the Superscript III First Strand Synthesis kit (Invitrogen).
Invasion and migration assays
The invasion or migration capability of glioma cells was assessed using 24-well transwell con-
taining an 8-mm pore size poly-carbonate membrane with or without matrigel-coated mem-
brane matrix. Cells (2 x 105/ml) were resuspended in 200 μl of serum-free medium. The cells
were then plated on the top side of polycarbonate Transwell filter (without matrigel for Trans-
well assay) or plated on the top side of polycarbonate Transwell filter coated with Matrigel (for
Transwell matrix penetration assay) in the upper chamber of the BioCoat Invasion Chambers
(BD) and incubated at 37˚C for 48 h, followed by removal of cells on the upper chamber with
cotton swabs. Migrated and invaded cells on the lower membrane surface were fixed in 4%
formaldehyde and stained with 0.1% of crystal violet for 5 min. Randomly selected five fields
of cells in each well were counted under a microscope at 200 x magnification.
Human tumor xenografts in severe combined immunodeficient (SCID)
mice
To test the effect of AS-1411 in vivo, a xenograft model of human glioma was established.
4-week old male SCID mice were purchased from Vital River Laboratory Animal Technology
(Beijing, China). After 1-week acclimatization, mice were subcutaneously injected in the right
flank with 5×106 U87 cells re-suspended in 50 ul DMEM media. Treatment was initiated when
the subcutaneous tumors reached an average size of 150 to 200mm3. Specifically, AS1411 or
aptamer control sequence (C-rich sequence; CRO) was subcutaneously injected (adjacent to
the tumor area). One injection every 5 days (5μM), for 20 days. Mice received intraperitoneal
injection of AS1411 and vehicle as control. Tumor diameter was measured every 2 days with
calipers, and the tumor volume was calculated (length×width×height×0.5). Euthanasia was
used in the animal experiment to minimized animal suffering and distress. Specific signs indi-
cated “humane endpoints” are ruffled fur, 15–20% weight loss and over 15 mm of tumor diam-
eter. We used 70% CO2 for 40 sec to terminate life of animals that reached humane endpoints.
We monitored the health of animals every 24 hours and no unexpected death was found. All
experiments were carried out in keeping with the procedures and protocols of the Animal Eth-
ics Committee of the First Hospital of Jilin University.
Results
High expression of NCL in glioma cells and its high affinity to AS1411
It was reported that GBM cells express high level of NCL [18]. In our study, Immunohisto-
chemical staining and Real-time qPCR results demonstrated significantly increased cyto-
plasmic level of NCL in GBM tissues compared with normal brain samples (Fig 1a–1c). Also,
Real-time qPCR showed significantly higher NCL mRNA levels in glioma U87, U251 and
SHG44 cells than that in NHA (Fig 1d). Consistent with difference of mRNA levels, immuno-
blotting analyses demonstrated that NCL was overexpressed in glioma cells when compared to
NHA (Fig 1e). To determine the subcellular localization of NCL, immunofluorescence staining
of NCL was performed in U87 and NHA cells. The results showed that NCL was highly stained
in both nucleus and cytoplasm in U87 cells but only stained in nucleus in NHA (Fig 1f).
Effect of AS1411 on Glioma via Nucleolin
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Fig 1. Expression of NCL in glioma cells and NHA and its binding affinity to AS1411. (a) Relative mRNA level of NCL in 40
clinical GBM tissues analyzed by Real-time qPCR. (b) Real-time qPCR detection of mRNA level of NCL in clinical GBM tissues
compared to normal brain tissues (c) Immunohistochemical staining of NCL in GBM and normal brain tissues (Astrocytes). Scale bar
equals 50 μm. (d) Real-time qPCR detection of NCL mRNA in human glioma cells: U87, U251, SHG44 and normal NHA cell. (e)
Immunoblotting detection of NCL protein in U87, U251 and SHG44 cells compared to NHA, β-actin was used as loading control. (f)
Effect of AS1411 on Glioma via Nucleolin
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Similar subcellular localization of NCL was found in breast cancer MCF7 cells and normal epi-
thelial MCF10A cells [9]. Hence, NCL is over-expressed in both nucleolus and cytoplasm in
glioma cells.
AS1411 was shown to bind NCL and inhibited the growth of malignant breast cancer cells
[9]. To assess the binding of AS1411 to NCL in glioma cells, U87 cells were treated with FIT-
C-AS1411 for 2h. Detection of FITC-AS1411 and NCL was performed by immunofluores-
cence staining. As shown in Fig 1g, the majority of AS1411 co-localized NCL in both nucleus
and cytoplasm in U87 cells. Thus, AS1411 binds NCL [19], suggesting a potential effect of
AS1411 in growth inhibition in glioma cells.
Exposure to AS1411 results in significant growth inhibition in glioma cells
compared to NHA
Obvious dose-and time-dependent growth inhibitions induced by AS1411 were observed in
U87, U251 and SHG44 cells (Fig 2a). At clinically achievable concentration of AS1411 (5μM)
[20], significant cell inhibitory effects were found in glioma cells after exposure to AS1411
(5μM) for 48h (Fig 2a and 2b) but not in NHA. No significant growth inhibition by CRO at
5μM was detected in all the tested cells (Fig 2b). In order to find the effect of AS1411 on cell
morphology, the light microscope images of U87 and U251 cells after treatment of AS1411 for
48 h were collected. As shown in Fig 2c, the cell number decreased in the AS1411 group
(2.5μM and 5μM) compared to CRO group in both U87 and U251 cells. Besides, AS1411
treated cells demonstrated apopotic cell morphology. These results showed that AS1411 can
induce the anti-proliferate effect on glioma cells but not on NHA within a certain range of
concentration. Moreover, the inhibitory effect induced by AS1411 on wt-p53 cell lines (U87
and SHG44) is stronger than that on mutant-p53 cell line (U251) after 72 h treatment (S2 Fig).
AS1411 induces the up-regulation of p53 and down-regulation of Bcl-2
and Akt1 via NCL in glioma cells
AS1411 has the potential to compete binding the C-terminal region of NCL thereby disabling
the function of the NCL to certain mRNAs such as the mRNAs of p53, Bcl-2 and Akt1 [21].
NCL usually binds with the 3’UTR (such as Bcl-2), 5’UTR (p53) and both (Akt 1) terminals of
mRNAs. p53 and Bcl-2 play a pivotal role in the regulation of cell death, while Akt1 controls
cell cycle, invasion and migration. To explore the mechanism of the growth inhibition by
AS1411 in human malignant glioma cells, we examined the mRNA and protein levels of p53,
Bcl-2 and Akt1 in U87 and U251 cells following exposure to AS1411. After 48 h, AS1411 treat-
ment significantly increased p53 mRNA and decreased Bcl-2 and Akt1 mRNAs in both U87
and U251 in a time-depended manner (Fig 3a). Similarly, treatment with AS1411 on U87 and
U251 cells for 48 h resulted in up-regulation of p53 and down-regulation of Bcl-2 and Akt1 in
protein levels in a doze-depended manner (Fig 3b). Further, we found NCL binding 5 UTR of
p53 mRNA was antagonized by AS1411, which indicates p53 is transcriptionally regulated by
AS1411 via NCL (S3 Fig).
To assess whether the above effects result from disruption of functions of NCL by AS1411,
NCL was silenced by siRNA in U87 and U251 cells (S4 Fig). Knockdown of NCL by siRNA led
to significant upregulation of p53 mRNA and downregulation of the mRNA levels of Bcl-2
Immunofluorescence detection of the expression and location of NCL in U87 and NHA cells. (g) Immunofluorescence detection of
FITC-AS1411 (green) and NCL (red) co-localizations in glioma cells. Error bars indicate ± s.d. *P< 0.05, **P< 0.01, two-tailed
student’s t-test. Scale bar equals 20 μm.
doi:10.1371/journal.pone.0167094.g001
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and Akt1 (Fig 3c). In addition, silencing of NCL increased p53 and decreased Bcl-2 and Akt1
proteins in both U87 and U251 (Fig 3d). These results showed that silencing NCL or treatment
with AS1411 up-regulated p53 and down-regulated Bcl-2 and Akt1 at both mRNA and protein
levels, which indicated a similar effect of the treatment of AS1411 as NCL siRNA. These results
suggest that up-regulation of p53 and down-regulation of Bcl-2 and Akt1 is a result of the NCL
dysfunction induced by AS1411.
AS1411 induces G2/M cell cycle arrest via NCL dysfunction in glioma
cells
A previous study showed that reduction of NCL expression through siRNA-mediated knock-
down in the U87 cell caused a dramatic decrease in cell proliferation and induced cell cycle
Fig 2. Short term AS1411 exposure induced growth suppression in glioma cells. (a) MTT analysis of cell viability after exposure to AS1411 from 0 to
80 μM for 48, 72 and 96h in U87, U251, SHG44 and NHA cells, respectively. (b) After 48 h treatment. Cell viability inhibition induced by AS1411 in glioma
cells was compared to that in NHA cells. (c) 10×Light microscope images indicated the growth inhibition and cell structure destroy in U87 and U251 cells
induced by AS1411 of 0 to 5μM and CRO of 5μM for 48 h. Error bars indicate ± s.d. *P<0.05, two-tailed student’s t-test. Scale bar equals 10 μm.
doi:10.1371/journal.pone.0167094.g002
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Fig 3. Expression of Bcl-2, p53, Akt1 after AS1411 treatment and NCL silencing in U87 and U251 cells. (a) Real-time qPCR
detection of Bcl-2, p53 and Akt1 mRNA in U251 and U87 cells after treatment with AS1411 (5 μM) for 48 h, 72 h and 96 h. (b)
Immunoblotting analysis of Bcl-2, p53 and Akt1 in U251 and U87 cells treated with AS1411 (5 μM) for 48 h, β-actin used as loading
control. (c) Real-time qPCR detection of Bcl-2, p53 and Akt1 mRNA after siRNA NCL silencing in U87 cells and U251 cells for 48 h.
Immunoblotting detection of p53, Bcl-2 and Akt1 after siRNA NCL silencing in U87 and U251 cells for 48 h. (d) Error bars
indicate ± s.d. *P<0.05, **P< 0.01, two-tailed student’s t-test.
doi:10.1371/journal.pone.0167094.g003
Effect of AS1411 on Glioma via Nucleolin
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arrest in vitro [22]. The similar patterns of the up-regulation of p53 and down-regulation of
Bcl-2 and Akt1 by NCL siRNA and AS1411 suggest AS1411 may have the ability to cause cell
cycle arrest in glioma cells. To this end, U87, U251, SHG44 and NHA cells were exposed to
5μM AS1411 or 5μM CRO for 48h and cell cycle distribution was analyzed with PI staining
and flow cytometry. AS1411 induced an increase of cells in G2-M phase with concomitant
decrease of cells in the G0 and G1 phases in U87, U251 and SHG44 but not NHA cells (Fig 4a
and 4b). Furthermore, AS1411 increased the protein levels of cyclin A1 and decreased the pro-
tein levels of cyclin B1 in both U87 and U251 cells. No obvious alteration of cyclin D1 by
AS1411 was observed in both cell lines (Fig 4c). Interestingly, overexpression of NCL signifi-
cantly prevented induction of the G2/M cell cycle arrest by AS1411 in both U87 and U251
cells (Fig 4d). These results indicated that AS1411 is able to perturb the cell cycle progression
of glioma cells by inducing NCL dysfunction.
AS1411 induces apoptosis in a p53 and Bcl-2 dependent manner in
glioma cells
We explored whether NCL interference by AS1411 results in cell apoptosis in glioma cells.
Firstly, we performed the staining of cells with Annexin V and PI, followed by analysis with
flow cytometry. The proportion of apoptotic cells with Annexin V staining was increased in a
dose-dependent manner in U87, U251 and SHG44 cells compared to NHA after treatment of
AS1411 for 48h (Fig 5a). In addition, AS1411 increased Annexin V staining in a time-depen-
dent way in U87, U251 and SHG44 cells but not in NHA cells (Fig 5b). However, overexpres-
sion of Bcl-2 significantly reduced the induction of apoptosis by AS1411 in both U87 and
U251 cells. Silencing of p53 by siRNA also inhibited cell apoptosis in U87 cell (Fig 5c). Further
research is needed to access whether silencing of p53 can result the same effect in U251 since
U251 is one of the p53-mutant cell lines [23]. It has been reported that AS1411 reduced NCL
binding to Bcl-2 mRNA resulting in BCL2 mRNA destabilization and downregulation of Bcl-2
protein levels [9, 24–25]. Besides, Bcl-2 is also repressed by p53 [26]. Our results suggest
AS1411 may induce cell apoptosis in glioma cells by influencing p53 and Bcl-2 mRNA via
NCL.
AS1411 inhibits cell migration and invasion of glioma cells in vitro by
down regulation of Akt1
Previous studies showed that Akt1 mRNA has the ability to bind to NCL [27]. The activation
of AKT promotes glioma invasiveness, angiogenesis and migration. The suppression of the
expression of Akt1 by AS1411 (Fig 3a and 3b) suggests that AS1411 may reduce the glioma
invasiveness and metastasis. Indeed, AS1411 significantly reduced the migration of U87, U251
and SHG44 cells in a dose dependent manner but not NHA cells (P<0.05; Fig 6a). Further,
AS1411 significantly reduced the invasion ability of U87, U251 and SHG44 cells in a dose
dependent way but not NHA cells (P<0.05; Fig 6b). In sharp contrast, ectopic overexpression
of Akt1 significantly abolished the suppression of the migration (P<0.05; Fig 6a) and invasion
(P<0.05; Fig 6b) of U87, U251 and SHG44 cells. These results indicate that AS1411 inhibits
glioma cell migration and invasion by reducing Akt1 in glioma cells.
AS1411 has anti-tumor activity in xenograft models
To examine anti-tumor effects of AS1411 in vivo, a human glioma-SCID mouse model using
the U87 cell was established. As shown in Fig 7a, AS1411 treatment (25mg/kg) remarkably
prolonged the survival of tumor-bearing mice (P<0.05). In addition, the mice that received
Effect of AS1411 on Glioma via Nucleolin
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Fig 4. G2/M cell cycle arrest evoked by AS1411. (a) Cell cycle arrest induced by AS1411 in U87, U251, SHG44 and NHA cells. 48 h after
treatment with AS1411 (5μM), cells were collected and stained with propidium iodide (PI); DNA content was determined by flow cytometry.
This assay was performed in triplicate. CRO (5μM) was used as negative control. (b) Histograms showing the percentage of glioma cells and
NHA in G0-G1, S, and G2-M phases in four independent experiments. (c) The G2/M cell cycle related protein cyclin A1, cyclin B1 and cyclin
D1 was detected by immunoblotting after treatment with AS1411 (5μM) for 48 h, CRO (5μM) was used as negative control, β-actin was used
Effect of AS1411 on Glioma via Nucleolin
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AS1411 treatment had a lower tumor burden as compared with the control group (P<0.05; Fig
7b). These results demonstrated AS1411 inhibited the growth of U87 xenograft and prolonged
the survival time of glioma tumor-bearing mice. Further, we found a down-regulation of Bcl-2
and up-regulation of p53 protein in tumor tissue after treatment with AS1411 (Fig 7c).
Discussion
AS1411 was reported to have the ability to bind NCL [28, 29]. In this study, we demonstrated
that NCL was over-expressed in glioma cells and tissues. AS1411 co-localized NCL and inhib-
ited the proliferation, migration and invasion of glioma cells, accompanied with induction of
apoptosis and cell cycle arrest at G2/M phase. Moreover, either silencing NCL or AS1411 up-
regulated p53 while down-regulated Bcl-2 and Akt1. Importantly, AS1411 inhibited the
growth of U87 xenograft and prolonged the survival time of glioma tumor-bearing mice. Our
results indicated that AS1411 inhibited the growth of glioma cells via disrupting the functions
of NCL, suggesting a promising further development of AS1411 for the treatment of glioma
patients in clinic.
NCL presents in the nucleoli, nucleoplasm, cytoplasm, and plasma membrane of cells [30–
31]. It plays an important role in ribosome biogenesis, which include the control of rDNA
transcription, pre-ribosome packaging, and organization of nucleolar chromatin. NCL is also
a shuttle protein that transports viral and cellular proteins between the cytoplasm and nucleus/
nucleolus. NCL has also been implicated, directly or indirectly, in the regulation of many other
biology processes including apoptosis, nuclear matrix structure, DNA replication, mRNA sta-
bility, transcriptional regulation, signal transduction, telomere maintenance, cytokinesis, as a
nucleic acid helicase, and as a G-quadruplex binding protein. In addition, there are numerous
reports describing the presence of NCL on the cell surface and its function as a receptor for a
variety of ligands [19, 32–33]. Because of the multifunctional nature of NCL, it has been pro-
posed that many secondary targets are affected following treatment with AS1411 [34]. NCL is
higher expressed in tumor cells than in normal cells [35–36], besides, NCL expresses in cell
membrane, cytoplasm and nucleus in tumor cells while only within nucleus in normal cells
[29, 37], AS1411 binds NCL on external surface of the cell and then is internalized [9]. Express-
ing only nucleus NCL, NHA is weakly respond to AS1411 mainly due to the limited internali-
zation and interaction with NCL.
NCL has been reported to have the ability to interfere with DNA and mRNA of several pro-
teins [38–39]. The C-terminal region of NCL contains anarginine/glycine-rich domain (RGG),
through which NCL can interact with target mRNAs as well as other proteins like ribosomal
proteins [40–41]. The sequence of AS1411 is similar to many NCL target mRNAs, suggesting
AS1411 has the potential to compete binding the C-terminal region of NCL [21]. Many of
NCL target mRNAs bear AU-rich elements (AREs), typically present in their 3’-untranslated
region (UTR), and/or G-rich sequences distributed in the 5’ UTR, coding region (CR), and 3’
UTR [42]. Our study showed NCL siRNA silencing resulted in the down-regulation of Bcl-2
and up-regulation of p53, which may be explained by the interaction between NCL and 3’
UTR of Bcl-2 mRNA [24] and 5’ UTR of p53 mRNA [43]. The binding between NCL and Bcl-
2 mRNA promotes the expression of proto-oncogene Bcl-2, which blocks apoptosis in cancer
cells [24], while the binding between NCL and p53 mRNA reduces the translation of the pro-
apoptotic tumor suppressor p53, further enhancing an anti-apoptotic cell phenotype [43–44].
We found that treatment of AS1411 and NCL silencing by siRNA had the same effect on the
as loading control. (d) Histograms showing the percentage of glioma cells in G0-G1, S, and G2-M phases after the NCL overexpression. Error
bars indicate ± s.d. **P<0.01, two-tailed student’s t-test.
doi:10.1371/journal.pone.0167094.g004
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Fig 5. Apoptosis induced by AS1411 in glioma cells. (a) Apoptotic cell death induced by AS1411 in U87, U251, SHG44 and NHA
cells. 48h after treatment, cells were collected and stained with PI and Annexin V–FITC, Annexin V-positive/PI-negative cells were
measured by flow cytometry. This experiment was repeated three times. (b) Histograms showing the percentage of cells in
apoptosis. U87, U251, SHG44 and NHA cells in four independent experiments. Annexin V-positive cells were considered as
apoptotic cells. (c) Histograms showing the percentage of glioma cells apoptosis after the Bcl-2 overexpression and p53 siRNA
silencing. Error bars indicate ± s.d. **P<0.01, two-tailed student’s t-test.
doi:10.1371/journal.pone.0167094.g005
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Fig 6. Migration and invasion inhibition induced by AS1411. (a) AS1411 inhibited the migration of glioma cells in vitro. The
migration capabilities of U87, U251, SHG44 and NHA cells were assessed after pretreatment with AS1411 of 0 to 10 μM and
CRO of 10μM. Akt1 overexpression antagonized AS1411 induced migration inhibition. (b) AS1411 inhibited the invasion of
glioma cells in vitro. The invasive capabilities of U87, U251, SHG44 and NHA were assessed after pretreatment with AS1411
of 0 to 10μM and CRO of 10μM. Akt1 overexpression antagonized AS1411 induced invasion inhibition. Error bars indicate s.d.
*P<0.05, **P<0.01, two-tailed Student’s t-test.
doi:10.1371/journal.pone.0167094.g006
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expression of Bcl-2 and p53 in glioma cells. The up-regulation of p53 and down-regulation of
Bcl-2 is responsible for the cell apoptosis. Our results showed that the induction of apoptosis
by AS1411 was abolished by the over-expression of Bcl-2 and silencing of p53. Our findings
suggest that the interaction of AS1411 to the binding site of NCL lead to the up-regulation of
p53 and down-regulation of Bcl-2.
Literature previously reported the enhanced translation of a subset of target mRNAs by
interacting with G-rich elements present in both CR and UTRs [45–47]. These mRNAs
include those that encode the pro-survival proteins Akt1. By binding to Akt1 mRNA, NCL
enhances the translation of Akt1 to promote the survival of the malignant cells. In this study,
we showed that both treatment of AS1411 and NCL silencing by siRNA decreased Akt1 in gli-
oma cells, which is consistent with previous studies [48–49], and suggest the down-regulation
Fig 7. Tumor growth inhibition and life expansion induced by AS1411 in vivo. Subcutaneous tumors generated from U87 cells were allowed to
reach a volume of 200 mm3 and were treated with AS1411 and CRO. (a) Survival of brain tumor–bearing mice was recorded and represented in a
Kaplan–Meier plot. (b) Tumor volume during the course of treatment. (c) AS1411 treatment (20 days) induced down-regulation of Bcl-2 and up-
regulation of p53 protein in tumor tissue. *P<0.05, **P<0.01, two-tailed Student’s t-test.
doi:10.1371/journal.pone.0167094.g007
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of the Akt1 is one of the mechanisms that responsible for AS1411-induced migration and inva-
sion inhibition of glioma cells.
Previous studies has shown that the siRNA knockdown of NCL leads to cell cycle arrest in
HeLa cells [50], and in U87 cells [22]. Also, AS1411 can induce an S-phrase cell cycle arrest
in gastric cancer cells [51] and PC3 cancer cells [52]. While in our study, obvious G2/M
arrest was induced by AS1411 in U87 and U251 cells. The C-terminal of NCL was reported
to have the ability of regulate the cell cycle progression [32]. Considering the same effects
induced by AS1411 and NCL siRNA, we evaluated the effect of AS1411 on the cell cycle pro-
gression and revealed AS1411 induced G2/M cell cycle arrest, accompanied with the up-reg-
ulation of cyclin A1 and down-regulation of cyclin B1, which are responsible for the G2/M
cell cycle arrest [32].
Preclinical mouse models have shown a great promise of AS1411 for the treatment of sev-
eral solid tumors [53]. Our results showed a reduction of tumor volume and extension of sur-
vival period in glioma xenograft models, suggesting a promising of AS1411 in the future
clinical application in the therapy of glioma. In phase I trial, AS1411 has been tested without
serious systemic toxicity to patients. Moreover, AS1411 can be heated to 80˚C or stored in var-
ious solvents/harsh environments, and will return to their original conformation. Further-
more, aptamers may penetrate tumors better and be more rapidly cleared from the blood.
Notably, AS1411 also appears to bind to NCL in cell surface specifically, and is subsequently
internalized into the tumor cell. We therefore propose AS1411 as possible adjuvant agent to
the standard therapeutic protocols presently utilized for glioma.
In conclusion, AS1411 induced cell apoptosis and cycle arrest, and inhibited cell viability by
up-regulation of p53 and down-regulation of Bcl-2 and Akt1 in human glioma cells compared
to NHA cell. Most importantly, AS1411 inhibited the growth of mouse glioma xenograft and
prolonged the survival time of glioma tumor-bearing mice. Furthermore, targeting NCL
means AS1411 may induce a stronger curative effect on high grade glioma which expresses
higher level of NCL [19, 54]. In all, our results suggest a promising further development of
AS1411 for the treatment of glioma patients in clinic.
Supporting Information
S1 Fig. Differentiation of astrocyte from stem cells. (a) Immunofluorescence detection of
glial fibrillary acidic protein (GFAP) positive cells. (b) Percentage of GFAP-positive cells in
total cells after treatment with trypsin. (Scale bar = 10μm).
(TIF)
S2 Fig. AS1411 induced growth suppression in wt-p53 cell lines vs mutant-p53 cell line.
MTT analysis of cell viability after exposure to AS1411 5μM for 48 and 72h in U87, U251,
SHG44 cells, respectively. Though significant growth inhibitions were found in all of the 3 cell
lines (Fig 2), AS1411 induced a stronger growth suppression in wt-p53 cell lines (U87 and
SHG44) compared to mutant-p53 cell line (U251) in 72 h after treatment. P<0.05, two-tailed
student’s t-test.
(TIF)
S3 Fig. RNA pull down assay. Whole cell extract (WCE) prepared from U87 cell after treat-
ment with AS1411 5μM for 48 h, and the binding of nucleolin protein to biotinylated p53 5’
UTR was tested. Then the bound fractions are analyzed by immunoblotting.
(TIF)
S4 Fig. siRNA knockdown of Nucleolin. (a) Immunoblotting detection of NCL in nuclear
extract (NE), cytosolic extract (CE) and whole cell extracts (WCE) after NCLsi. (b) Then the
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percentage of NCL protein in nuclear, cytosolic and whole cell extracts after NCLsi compared
with control group (100%) was calculated.
(TIF)
S5 Fig. Tumor volume analysis after AS1411 treatment for 30 days. Tumor volume
decreased significantly after treatment with AS1411 5μM for 30 days. P<0.01, two-tailed stu-
dent’s t-test.
(TIF)
S1 File. Supplementary Methods.
(DOCX)
Acknowledgments
This work was supported by the Young Scientists Fund of the National Natural Science Foun-
dation of China (No.21401072); This work was supported by China Scholarship Council.
Author Contributions
Conceptualization: Y. Chen YL.
Data curation: SZ.
Formal analysis: SZ.
Funding acquisition: Y. Chen.
Investigation: Y. Cheng, GZ ZY.
Methodology: Y. Chen.
Supervision: GZ.
Validation: GZ YS.
Writing – original draft: Y. Cheng.
Writing – review & editing: FN.
References
1. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. Radiotherapy plus con-
comitant and adjuvant temozolomide for glioblastoma. The N Engl J Med. 2005; 352, 987–996. doi: 10.
1056/NEJMoa043330 PMID: 15758009
2. Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, et al. Effects of radiother-
apy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma
in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009; 10:
459–466. doi: 10.1016/S1470-2045(09)70025-7 PMID: 19269895
3. Roos WP, Batista LF, Naumann SC, Wick W, Weller M, Menck CF, et al. Apoptosis in malignant glioma
cells triggered by the temozolomide-induced DNA lesion O6-methylguanine. Oncogene. 2007; 26:
186–197. doi: 10.1038/sj.onc.1209785 PMID: 16819506
4. Opalinska JB, Gewirtz AM. Nucleicacid therapeutics: basic principles and recent applications. Nat Rev
Drug Discov. 2002; 1: 503–514. doi: 10.1038/nrd837 PMID: 12120257
5. Gleave ME, Monia BP. Antisense therapy for cancer. Nat Rev Cancer. 2005; 5: 468–479. doi: 10.1038/
nrc1631 PMID: 15905854
6. Bates PJ, Laber DA, Miller DM, Thomas SD, Trent JO. Discovery and development of the G-rich oligo-
nucleotide AS1411 as a novel treatment for cancer. Exp Mol Pathol. 2009; 86: 151–164 doi: 10.1016/j.
yexmp.2009.01.004 PMID: 19454272
Effect of AS1411 on Glioma via Nucleolin
PLOS ONE | DOI:10.1371/journal.pone.0167094 December 1, 2016 17 / 20
7. Mongelard F, Bouvet P. AS-1411, a guanosine-rich oligonucleotide aptamer targeting nucleolin for the
potential treatment of cancer, including acute myeloid leukemia. Curr Opin Mol Ther. 2010; 12: 107–
114 PMID: 20140822
8. Teng Y, Girvan AC, Casson LK, Pierce WM Jr, Qian M, Thomas SD. AS1411 alters the localization of a
complex containing protein arginine methyltransferase 5 and nucleolin. Cancer Res. 2007; 67: 10491–
10500. doi: 10.1158/0008-5472.CAN-06-4206 PMID: 17974993
9. Soundararajan S, Chen W, Spicer EK, Courtenay-Luck N, Fernandes DJ. The nucleolin targeting apta-
mer AS1411 destabilizes Bcl-2 messenger RNA in human breast cancer cells. Cancer Res. 2008; 68:
2358–2365. doi: 10.1158/0008-5472.CAN-07-5723 PMID: 18381443
10. Ma H, Gao Z, Yu P, Shen S, Liu Y, Xu B. A dual functional fluorescent probe for glioma imaging medi-
ated by blood-brain barrier penetration and glioma cell targeting. Biochem Biophys Res Commun.
2014; 449: 44–48 doi: 10.1016/j.bbrc.2014.04.148 PMID: 24802402
11. Gao H, Yang Z, Zhang S, Pang Z, Liu Q, Jiang X. Study and evaluation of mechanisms of dual targeting
drug delivery system with tumor microenvironment assays compared with normal assays. Acta Bioma-
ter. 2014; 10: 858–867 doi: 10.1016/j.actbio.2013.11.003 PMID: 24239900
12. Goldshmit Y, Trangle SS, Kloog Y, Pinkas-Kramarski R. Interfering with the interaction between ErbB1,
nucleolin and Ras as a potential treatment for glioblastoma. Oncotarget. 2014; 30: 8602–8613
13. Storck S, Shukla M, Dimitrov S, Bouvet P. Functions of the histone chaperone nucleolin in diseases.
Subcell Biochem. 2007; 41: 125–144 PMID: 17484127
14. Xu Z, Joshi N, Agarwal A, Dahiya S, Bittner P, Smith E, et al. Knocking down nucleolin expression in gli-
omas inhibits tumor growth and induces cell cycle arrest. J Neurooncol. 2012; 108: 59–67 doi: 10.1007/
s11060-012-0827-2 PMID: 22382782
15. Mu Q, Wang L, Yu F, Gao H, Lei T, Li P, et al. Imp2 regulates GBM progression by activating IGF2/
PI3K/Akt pathway. Cancer Biol Ther. 2015; 16: 623–633 doi: 10.1080/15384047.2015.1019185 PMID:
25719943
16. Chen Y, Qu K, Zhao C, Wu L, Ren J, Wang J, et al. Insights into the biomedical effects of carboxylated
single-wall carbon nanotubes on telomerase and telomeres. Nat Commun. 2012; 3: 1074 doi: 10.1038/
ncomms2091 PMID: 23011128
17. Cheng Y, Li Y, Ma C, Song Y, Xu H, Yu H, et al. Arsenic trioxide inhibits glioma cell growth through
induction of telomerase displacement and telomere dysfunction. Oncotarget. 2016; 7: 12682–12692
doi: 10.18632/oncotarget.7259 PMID: 26871293
18. Huang PH, Xu AM, White FM. Oncogenic EGFR signaling networks in glioma. Science signaling. 2009;
2: re6 doi: 10.1126/scisignal.287re6 PMID: 19738203
19. Galzio R, Rosati F, Benedetti E, Cristiano L, Aldi S, Mei S, et al. Glycosilated nucleolin as marker for
human gliomas. J Cell Biochem. 2012; 113: 571–579. doi: 10.1002/jcb.23381 PMID: 21938743
20. Rosenberg JE, Bambury RM, Van Allen EM, Drabkin HA, Lara PN Jr, Harzstark AL, et al. A phase II
trial of AS1411 (a novel nucleolin-targeted DNA aptamer) in metastatic renal cell carcinoma. Invest New
Drugs. 2014; 32: 178–187 doi: 10.1007/s10637-013-0045-6 PMID: 24242861
21. Bra´zda V, Ha´ronı´kova´ L, Liao JC, Fojta M. DNA and RNA quadruplex-binding proteins. Int J Mol Sci.
2014; 15: 17493–17517 doi: 10.3390/ijms151017493 PMID: 25268620
22. Xu Z, Joshi N, Agarwal A, Dahiya S, Bittner P, Smith E et al. Knocking down nucleolin expression in glio-
mas inhibits tumor growth and induces cell cycle arrest. J Neurooncol. 2012; 108: 59–67 doi: 10.1007/
s11060-012-0827-2 PMID: 22382782
23. Luan S, Sun L, Huang F. MicroRNA-34a: a novel tumor suppressor in p53-mutant glioma cell line U251.
Arch Med Res. 2010; 41: 67–74 doi: 10.1016/j.arcmed.2010.02.007 PMID: 20470934
24. Ishimaru D, Zuraw L, Ramalingam S, Sengupta TK, Bandyopadhyay S, Reuben A, et al. Mechanism of
regulation of bcl-2 mRNA by nucleolin and A + U-rich element-binding factor 1 (AUF1). J Biol Chem.
2010; 285: 27182–27191. doi: 10.1074/jbc.M109.098830 PMID: 20571027
25. Willimott S, Wagner SD. Post-transcriptional and posttranslationalregulation of Bcl2. Biochem Soc
Trans. 2010; 38: 1571–1575 doi: 10.1042/BST0381571 PMID: 21118128
26. Wu Y, Mehew JW, Heckman CA, Arcinas M, Boxer LM. Negative regulation of bcl-2 expression by p53
in hematopoietic cells. Oncogene. 2001; 20: 240–251. doi: 10.1038/sj.onc.1204067 PMID: 11313951
27. Abdelmohsen K, Tominaga K, Lee EK, Srikantan S, Kang MJ, Kim MM, et al. Enhanced translation by
Nucleolin via G-rich elements in coding and noncoding regions of target mRNAs. Nucleic Acids Res.
2011; 39: 8513–8530 doi: 10.1093/nar/gkr488 PMID: 21737422
28. Koutsioumpa M, Papadimitriou E. Cell surface nucleolin as a target for anti-cancer therapies. Recent
Pat Anticancer Drug Discov. 2014; 9:137–152. PMID: 24251811
Effect of AS1411 on Glioma via Nucleolin
PLOS ONE | DOI:10.1371/journal.pone.0167094 December 1, 2016 18 / 20
29. Perrone R, Butovskaya E, Lago S, Garzino-Demo A, Pannecouque C, Palu` G, et al. The G-quadruplex-
forming aptamer AS1411 potently inhibits HIV-1attachment to the host cell. Int J Antimicrob Agents.
2016; 47: 311–316. doi: 10.1016/j.ijantimicag.2016.01.016 PMID: 27032748
30. Srivastava M, Pollard HB. Molecular dissection of nucleolin’s role in growth and cell proliferation: new
insights. FASEB J. 1999; 13: 1911–1922. PMID: 10544174
31. Mongelard F, Bouvet P. Nucleolin: a multifaceted protein. Trends Cell Biol. 2007; 17: 80–86 doi: 10.
1016/j.tcb.2006.11.010 PMID: 17157503
32. Huwiler A, Akool el-S, Aschrafi A, Hamada FM, Pfeilschifter J, Eberhardt W. ATP potentiates interleu-
kin-1beta-induced MMP-9 expression in mesangial cells via recruitment of the ELAV protein HuR. J
BiolChem. 2003; 278: 51758–51769
33. Benedetti E, Antonosante A, d’Angelo M, Cristiano L, Galzio R, Destouches D, et al. Nucleolin antago-
nist triggers autophagic cell death in human glioblastoma primary cells and decreased in vivo tumor
growth in orthotopic brain tumor model. Oncotarget. 2015; 6: 42091–42104. doi: 10.18632/oncotarget.
5990 PMID: 26540346
34. Mongelard F, Bouvet P. AS-1411, a guanosine-rich oligonucleotide aptamer targeting nucleolin for the
potential treatment of cancer, including acute myeloid leukemia. Curr Opin Mol Ther. 2010; 12: 107–
114 PMID: 20140822
35. Pich A, Chiusa L, Margaria E. Prognostic relevance of AgNORs in tumor pathology. Micron. 2000;
31:133–141 PMID: 10588059
36. Otake Y, Soundararajan S, Sengupta TK, Kio EA, Smith JC, Pineda-Roman M, et al. Overexpression of
nucleolin in chronic lymphocytic leukemia cells induces stabilization of bcl2 mRNA. Blood. 2007; 109:
3069–3075 doi: 10.1182/blood-2006-08-043257 PMID: 17179226
37. Ireson CR, Kelland LR. Discovery and development of anticancer aptamers. Mol Cancer Ther. 2006; 5:
2957–62 doi: 10.1158/1535-7163.MCT-06-0172 PMID: 17172400
38. Ginisty H, Sicard H, Roger B et al (1999) Structure and functions of nucleolin. J Cell Sci 112: 761–772
PMID: 10036227
39. Seinsoth S, Uhlmann-Schiffler H, Stahl H. Bidirectional DNA unwinding by a ternary complex of T anti-
gen, nucleolin and topoisomerase I. EMBO Rep. 2003; 4: 263–268 doi: 10.1038/sj.embor.embor770
PMID: 12634843
40. Bouvet P, Diaz JJ, Kindbeiter K, Madjar JJ, Amalric F. Nucleolin interacts with several ribosomal pro-
teins through its RGG domain. J Biol Chem. 1998; 273: 19025–19029 PMID: 9668083
41. Ghisolfi L, Kharrat A, Joseph G, Amalric F, Erard M. Concerted activities of the RNA recognition and the
glycine-rich C-terminal domains of nucleolin are required for efficient complex formation with pre-ribo-
somal RNA. Eur J Biochem. 1992; 209: 541–548 PMID: 1425660
42. Sengupta TK, Bandyopadhyay S, Fernandes DJ, Spicer EK. Identification of nucleolin as an AU-rich
element binding protein involved in bcl-2 mRNA stabilization. J Biol Chem. 2004; 279: 10855–10863.
doi: 10.1074/jbc.M309111200 PMID: 14679209
43. Takagi M, Absalon MJ, McLure KG, Kastan MB. Regulation of p53 translation and induction after DNA
damage by ribosomal protein L26 and nucleolin. Cell. 2005; 123: 49–63. doi: 10.1016/j.cell.2005.07.
034 PMID: 16213212
44. VlatkovićN, Boyd MT, Rubbi CP. Nucleolar control of p53: a cellular Achilles’ heel and a target for can-
cer therapy. Cell Mol Life Sci. 2014; 71: 771–791 doi: 10.1007/s00018-013-1361-x PMID: 23685903
45. Abdelmohsen K, Tominaga K, Lee EK, Srikantan S, Kang MJ, Kim MM, et al. Enhanced translation
byNucleolin via G-rich elements in coding and noncodingregions of target mRNAs. Nucleic Acids Res.
2011; 39: 8513–8530 doi: 10.1093/nar/gkr488 PMID: 21737422
46. Hers I, Vincent EE, Tavare´ JM. Akt signalling in health and disease. Cell Signal. 2011; 23: 1515–1527
doi: 10.1016/j.cellsig.2011.05.004 PMID: 21620960
47. Griffin SV, Olivier JP, Pippin JW, Roberts JM, Shankland SJ. Cyclin I protects podocytes from apopto-
sis. J BiolChem. 2006; 281: 28048–28057
48. Zhang G, Liu Z, Xu H, Yang Q. miR-409-3p suppresses breast cancer cell growth and invasion by tar-
geting Akt1. Biochem Biophys Res Commun. 2016; 469: 189–195 doi: 10.1016/j.bbrc.2015.11.099
PMID: 26631969
49. Ugrinova I, Monier K, Ivaldi C, Thiry M, Storck S, Mongelard F, et al. Inactivation of nucleolin leads to
nucleolardisruption, cell cycle arrest and defects in centrosome duplication. BMC Mol Biol. 2007; 8: 66.
doi: 10.1186/1471-2199-8-66 PMID: 17692122
50. Abdelmohsen K, Gorospe M. RNA-binding protein nucleolin in disease. RNA Biol. 2012; 9: 799–808
doi: 10.4161/rna.19718 PMID: 22617883
Effect of AS1411 on Glioma via Nucleolin
PLOS ONE | DOI:10.1371/journal.pone.0167094 December 1, 2016 19 / 20
51. Watanabe T, Hirano K, Takahashi A, Yamaguchi K, Beppu M, Fujiki H, et al. Nucleolin on the cell sur-
face as a new molecular target for gastric cancer treatment. Biol Pharm Bull. 2010; 33: 796–803 PMID:
20460757
52. Zhang H, Hou L, Jiao X, Yandan J, Zhu X, Hongji L, et al. In vitro and in vivo evaluation of antitumor
drug-loaded aptamer targeted single-walled carbon nanotubes system. Curr Pharm Biotechnol. 2014;
14: 1105–1117. PMID: 24725129
53. Pichiorri F, Palmieri D, De Luca L, Consiglio J, You J, Rocci A, et al. In vivo NCL targeting affects breast
cancer aggressiveness through miRNA regulation. J Exp Med. 2013; 210: 951–968 doi: 10.1084/jem.
20120950 PMID: 23610125
54. Gimenez M, Marie SK, Oba-Shinjo S, Uno M, Izumi C, Oliveira JB. Quantitative proteomic analysis
show differentially expressed HSPB1 in glioblastoma as a discriminating short from long survival factor
and NOVA1 as a differentiation factor between low-grade astrocytoma and oligodendroglioma. BMC
Cancer. 2015; 15: 481. doi: 10.1186/s12885-015-1473-9 PMID: 26108672
Effect of AS1411 on Glioma via Nucleolin
PLOS ONE | DOI:10.1371/journal.pone.0167094 December 1, 2016 20 / 20
